文献速递类风湿关节炎

类风湿关节炎生物制剂初治:托珠单抗与TNF抑制剂全球比较观察研究

Treatment of Rheumatoid Arthritis With Anti-Tumor Necrosis Factor or Tocilizumab Therapy as First Biologic Agent in a Global Comparative Observational Study.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2017-09-06

在全球26国158个中心前瞻性观察1216例对csDMARDs反应不足的RA患者,比较托珠单抗与TNF抑制剂作为首个生物制剂的疗效。托珠单抗组24周和52周DAS28-ESR改善更大,52周停药累积概率更低(15% vs 27%)。

要点

  • 托珠单抗组24周DAS28-ESR校正均值差为-0.831(95%CI -1.086至-0.576),优于TNFi。
  • 托珠单抗组52周停药累积概率15%,低于TNFi组的27%(P<0.001,未校正分析)。
  • 托珠单抗组严重不良事件和严重感染未校正频率低于TNFi组。

核心结论

  • 在观察性 settings 中,托珠单抗作为首个生物制剂在疗效和药物生存方面优于TNF抑制剂。

研究设计与样本

  • 前瞻性观察性研究,纳入1216例对csDMARDs反应不足并启动生物治疗的RA患者,在26国158个中心观察52周。
  • 35%患者启动托珠单抗(静脉),65%启动TNF抑制剂。
  • 主要终点为24周DAS28-ESR较基线变化,采用协方差分析进行组间比较。

主要发现

  • 托珠单抗组24周和52周DAS28-ESR改善均大于TNFi组,24周校正均值差为-0.831(95%CI -1.086至-0.576),P<0.001。
  • CDAI较基线变化托珠单抗组更大,24周校正均值差-3.48,52周-4.60,均P<0.001。
  • 托珠单抗组HAQ残疾指数改善优于TNFi组(P<0.05)。
  • 52周停药累积概率托珠单抗组15%,TNFi组27%(P<0.001,未校正分析)。
  • 未校正每100患者年事件频率:严重不良事件托珠单抗6.44 vs TNFi 11.99;严重感染1.98 vs 5.03;死亡0.74 vs 0.77。

关键数值与推荐

  • 主要终点DAS28-ESR 24周校正均值差-0.831(95%CI -1.086至-0.576),P<0.001。
  • CDAI校正均值差24周-3.48、52周-4.60,均P<0.001。
  • 52周停药累积概率托珠单抗15% vs TNFi 27%,P<0.001(未校正)。
  • 严重不良事件未校正频率托珠单抗6.44/100患者年 vs TNFi 11.99/100患者年。
  • 严重感染未校正频率托珠单抗1.98/100患者年 vs TNFi 5.03/100患者年。

临床怎么用

  • 对csDMARDs反应不足的RA患者,选择托珠单抗作为首个生物制剂可能获得比TNFi更大的疾病活动度改善。
  • 托珠单抗治疗者的52周药物生存率更高,严重不良事件和严重感染频率较低。
  • 需注意托珠单抗组基线疾病活动度和皮质激素使用更高、RA病程更短,解读结果时应考虑组间差异。

局限性

  • 为观察性研究,未随机化,组间基线特征存在差异。
  • 原文未报告对混杂因素进行调整后的安全性比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare clinical effectiveness between tocilizumab and tumor necrosis factor inhibitors (TNFi) in patients with rheumatoid arthritis (RA) and inadequate response to conventional synthetic disease-modifying antirheumatic drugs initiating biologic therapy. METHODS: Patients prescribed tocilizumab (intravenous) or TNFi were prospectively observed in routine clinical practice for 52 weeks across 158 sites in 26 countries. The primary observation was the change from baseline in Disease Activity Score based on 28 joints using the erythrocyte sedimentation rate (DAS28-ESR) at week 24 using analysis of covariance for between-groups comparison. Secondary end points included Clinical Disease Activity Index (CDAI) and patient-reported outcomes at weeks 24 and 52. RESULTS: Of 1,216 patients, 35% initiated tocilizumab and 65% initiated TNFi. RA duration was shorter, and disease activity and corticosteroid use were higher in tocilizumab patients. Tocilizumab-treated patients had greater improvement in DAS28-ESR at weeks 24 and 52 (week 24 difference [95% confidence interval] in adjusted means: -0.831 [-1.086, -0.576]; P < 0.001). Change from baseline in CDAI was also greater with tocilizumab (adjusted means difference: week 24, -3.48; week 52, -4.60; both P < 0.001). Tocilizumab-treated patients had more improvement in the Health Assessment Questionnaire disability index than TNFi-treated patients (P < 0.05). The cumulative probability of drug discontinuation at week 52 was lower with tocilizumab (15%) than TNFi (27%; P < 0.001, unadjusted analysis). Unadjusted frequencies (events per 100 patient-years) for tocilizumab and TNFi were 6.44 and 11.99 for serious adverse events, 1.98 and 5.03 for serious infections, and 0.74 and 0.77 for deaths, respectively. CONCLUSION: Patients initiating tocilizumab experienced greater effectiveness and drug survival than those initiating TNFi in an observational setting.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Choy EH, Bernasconi C, Aassi M, et al. Treatment of Rheumatoid Arthritis With Anti-Tumor Necrosis Factor or Tocilizumab Therapy as First Biologic Agent in a Global Comparative Observational Study. Arthritis Care Res (Hoboken). 2017. PMID: 28622454. doi:10.1002/acr.23303

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。